We are live on ! Find out more
NNNN

Anbio Biotechnology

5 hedge funds and large institutions have $894K invested in Anbio Biotechnology in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% less ownership

Funds ownership: 0.16%0.07% (-0.09%)

50% less funds holding

Funds holding: 105 (-5)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

65% less capital invested

Capital invested by funds: $2.54M → $894K (-$1.65M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
5
Holders Change
-5
Holders Change %
-50%
% of All Funds
0.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
1
Reduced
2
Closed
5
Calls
Puts
Net Calls
Net Calls Change

NNNN Hedge Fund Activity: Q4 2025 in Review

5 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q4 2025, worth a combined $894K — down 65% from $2.54M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NNNN and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $51.9K. The largest seller was Marshall Wace, exiting entirely with an estimated $389K sold.

  • 5 institutional investors held Anbio Biotechnology (NNNN) as of Q4 2025, down from 10 in Q3 2025.
  • Funds reported $894K of Anbio Biotechnology stock for Q4 2025, down 65% quarter-over-quarter.
  • 0 funds opened new Anbio Biotechnology positions in Q4 2025 and 5 closed out, a net change of -5 holders.
  • The largest Anbio Biotechnology buyer in Q4 2025 was UBS Group, an estimated $51.9K added.
  • The largest Anbio Biotechnology seller in Q4 2025 was Marshall Wace, an estimated $389K sold.

Based on aggregated 13F filings for Q4 2025.